pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-133a-1 |
Genomic Coordinates | chr18: 21825698 - 21825785 |
Synonyms | MIRN133A1, MIR133A1 |
Description | Homo sapiens miR-133a-1 stem-loop |
Comment | This miRNA sequence is predicted based on homology to a verified miRNA from mouse . |
RNA Secondary Structure | |
Associated Diseases | |
pre-miRNA | hsa-mir-133a-2 |
Genomic Coordinates | chr20: 62564912 - 62565013 |
Synonyms | MIRN133A2, MIR133A2 |
Description | Homo sapiens miR-133a-2 stem-loop |
Comment | This miRNA sequence is predicted based on homology to a verified miRNA from mouse . |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | ||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-133a-3p | |||||||||||||||||||||||||||
Sequence | 53| UUUGGUCCCCUUCAACCAGCUG |74 | |||||||||||||||||||||||||||
Evidence | Experimental | |||||||||||||||||||||||||||
Experiments | Cloned | DRVs in miRNA |
|
|||||||||||||||||||||||||
SNPs in miRNA |
|
|||||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Biomarker Information |
|
---|
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | ERG | ||||||||||||||||||||
Synonyms | erg-3, p55 | ||||||||||||||||||||
Description | ERG, ETS transcription factor | ||||||||||||||||||||
Transcript | NM_001136154 | ||||||||||||||||||||
Other Transcripts | NM_001136155 , NM_004449 , NM_182918 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on ERG | |||||||||||||||||||||
3'UTR of ERG (miRNA target sites are highlighted) |
>ERG|NM_001136154|3'UTR 1 AGACCTGGCGGAGGCTTTTCCCATCAGCGTGCATTCACCAGCCCATCGCCACAAACTCTATCGGAGAACATGAATCAAAA 81 GTGCCTCAAGAGGAATGAAAAAAGCTTTACTGGGGCTGGGGAAGGAAGCCGGGGAAGAGATCCAAAGACTCTTGGGAGGG 161 AGTTACTGAAGTCTTACTACAGAAATGAGGAGGATGCTAAAAATGTCACGAATATGGACATATCATCTGTGGACTGACCT 241 TGTAAAAGACAGTGTATGTAGAAGCATGAAGTCTTAAGGACAAAGTGCCAAAGAAAGTGGTCTTAAGAAATGTATAAACT 321 TTAGAGTAGAGTTTGGAATCCCACTAATGCAAACTGGGATGAAACTAAAGCAATAGAAACAACACAGTTTTGACCTAACA 401 TACCGTTTATAATGCCATTTTAAGGAAAACTACCTGTATTTAAAAATAGAAACATATCAAAAACAAGAGAAAAGACACGA 481 GAGAGACTGTGGCCCATCAACAGACGTTGATATGCAACTGCATGGCATGTGCTGTTTTGGTTGAAATCAAATACATTCCG 561 TTTGATGGACAGCTGTCAGCTTTCTCAAACTGTGAAGATGACCCAAAGTTTCCAACTCCTTTACAGTATTACCGGGACTA 641 TGAACTAAAAGGTGGGACTGAGGATGTGTATAGAGTGAGCGTGTGATTGTAGACAGAGGGGTGAAGAAGGAGGAGGAAGA 721 GGCAGAGAAGGAGGAGACCAGGGCTGGGAAAGAAACTTCTCAAGCAATGAAGACTGGACTCAGGACATTTGGGGACTGTG 801 TACAATGAGTTATGGAGACTCGAGGGTTCATGCAGTCAGTGTTATACCAAACCCAGTGTTAGGAGAAAGGACACAGCGTA 881 ATGGAGAAAGGGGAAGTAGTAGAATTCAGAAACAAAAATGCGCATCTCTTTCTTTGTTTGTCAAATGAAAATTTTAACTG 961 GAATTGTCTGATATTTAAGAGAAACATTCAGGACCTCATCATTATGTGGGGGCTTTGTTCTCCACAGGGTCAGGTAAGAG 1041 ATGGCCTTCTTGGCTGCCACAATCAGAAATCACGCAGGCATTTTGGGTAGGCGGCCTCCAGTTTTCCTTTGAGTCGCGAA 1121 CGCTGTGCGTTTGTCAGAATGAAGTATACAAGTCAATGTTTTTCCCCCTTTTTATATAATAATTATATAACTTATGCATT 1201 TATACACTACGAGTTGATCTCGGCCAGCCAAAGACACACGACAAAAGAGACAATCGATATAATGTGGCCTTGAATTTTAA 1281 CTCTGTATGCTTAATGTTTACAATATGAAGTTATTAGTTCTTAGAATGCAGAATGTATGTAATAAAATAAGCTTGGCCTA 1361 GCATGGCAAATCAGATTTATACAGGAGTCTGCATTTGCACTTTTTTTAGTGACTAAAGTTGCTTAATGAAAACATGTGCT 1441 GAATGTTGTGGATTTTGTGTTATAATTTACTTTGTCCAGGAACTTGTGCAAGGGAGAGCCAAGGAAATAGGATGTTTGGC 1521 ACCCAAATGGCGTCAGCCTCTCCAGGTCCTTCTTGCCTCCCCTCCTGTCTTTTATTTCTAGCCCCTTTTGGAACAGAAGG 1601 ACCCCGGGTTTCACATTGGAGCCTCCATATTTATGCCTGGAATGGAAAGAGGCCTATGAAGCTGGGGTTGTCATTGAGAA 1681 ATTCTAGTTCAGCACCTGGTCACAAATCACCCTTAATTCCTGCTATGATTAAAATACATTTGTTGAACAGTGAACAAGCT 1761 ACCACTCGTAAGGCAAACTGTATTATTACTGGCAAATAAAGCGTCATGGATAGCTGCAATTTCTCACTTTACAGAAACAA 1841 GGGATAACGTCTAGATTTGCTGCGGGGTTTCTCTTTCAGGAGCTCTCACTAGGTAGACAGCTTTAGTCCTGCTACATCAG 1921 AGTTACCTGGGCACTGTGGCTTGGGATTCACTAGCCCTGAGCCTGATGTTGCTGGCTATCCCTTGAAGACAATGTTTATT 2001 TCCATAATCTAGAGTCAGTTTCCCTGGGCATCTTTTCTTTGAATCACAAATGCTGCCAACCTTGGTCCAGGTGAAGGCAA 2081 CTCAAAAGGTGAAAATACAAGGTGACCGTGCGAAGGCGCTAGCCGAAACATCTTAGCTGAATAGGTTTCTGAACTGGCCC 2161 TTTTCATAGCTGTTTCAGGGCCTGTTTTTTTCACGTTGCAGTCCTTTTGCTATGATTATGTGAAGTTGCCAAACCTCTGT 2241 GCTGTGGATGTTTTGGCAGTGGGCTTTGAAGTCGGCAGGACACGATTACCAATGCTCCTGACACCCCGTGTCATTTGGAT 2321 TAGACGGAGCCCAACCATCCATCATTTTGCAGCAGCCTGGGAAGGCCCACAAAGTGCCCGTATCTCCTTAGGGAAAATAA 2401 ATAAATACAATCATGAAAGCTGGCAGTTAGGCTGACCCAAACTGTGCTAATGGAAAAGATCAGTCATTTTTATTTTGGAA 2481 TGCAAAGTCAAGACACACCTACATTCTTCATAGAAATACACATTTACTTGGATAATCACTCAGTTCTCTCTTCAAGACTG 2561 TCTCATGAGCAAGATCATAAAAACAAGACATGATTATCATATTCAATTTTAACAGATGTTTTCCATTAGATCCCTCAACC 2641 CTCCACCCCCAGTCCAGGTTATTAGCAAGTCTTATGAGCAACTGGGATAATTTTGGATAACATGATAATACTGAGTTCCT 2721 TCAAATACATAATTCTTAAATTGTTTCAAAATGGCATTAACTCTCTGTTACTGTTGTAATCTAATTCCAAAGCCCCCTCC 2801 AGGTCATATTCATAATTGCATGAACCTTTTCTCTCTGTTTGTCCCTGTCTCTTGGCTTGCCCTGATGTATACTCAGACTC 2881 CTGTACAATCTTACTCCTGCTGGCAAGAGATTTGTCTTCTTTTCTTGTCTTCAATTGGCTTTCGGGCCTTGTATGTGGTA 2961 AAATCACCAAATCACAGTCAAGACTGTGTTTTTGTTCCTAGTTTGATGCCCTTATGTCCCGGAGGGGTTCACAAAGTGCT 3041 TTGTCAGGACTGCTGCAGTTAGAAGGCTCACTGCTTCTCCTAAGCCTTCTGCACAGATGTGGCACCTGCAACCCAGGAGC 3121 AGGAGCCGGAGGAGCTGCCCTCTGACAGCAGGTGCAGCAGAGATGGCTACAGCTCAGGAGCTGGGAAGGTGATGGGGCAC 3201 AGGGAAAGCACAGATGTTCTGCAGCGCCCCAAAGTGACCCATTGCCTGGAGAAAGAGAAGAAAATATTTTTTAAAAAGCT 3281 AGTTTATTTAGCTTCTCATTAATTCATTCAAATAAAGTCGTGAGGTGACTAATTAGAGAATAAAAATTACTTTGGACTAC 3361 TCAAAAATACACCAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Article |
- Xiao J; Luo X; Lin H; Zhang Y; Lu Y; Wang et al. - The Journal of biological chemistry, 2007
We have previously found that the ether-a-go-go related gene (ERG), a long QT syndrome gene encoding a key K(+) channel (I(Kr)) in cardiac cells, is severely depressed in its expression at the protein level but not at the mRNA level in diabetic subjects. The mechanisms underlying the disparate alterations of ERG protein and mRNA, however, remained unknown. We report here a remarkable overexpression of miR-133 in hearts from a rabbit model of diabetes, and in parallel the expression of serum response factor (SRF), which is known to be a transactivator of miR-133, was also robustly increased. Delivery of exogenous miR-133 into the rabbit myocytes and cell lines produced post-transcriptional repression of ERG, down-regulating ERG protein level without altering its transcript level and caused substantial depression of I(Kr), an effect abrogated by the miR-133 antisense inhibitor. Functional inhibition or gene silencing of SRF down-regulated miR-133 expression and increased I(Kr) density. Repression of ERG by miR-133 likely underlies the differential changes of ERG protein and transcript thereby depression of I(Kr), and contributes to repolarization slowing thereby QT prolongation and the associated arrhythmias, in diabetic hearts. Our study provided the first evidence for the pathological role of miR-133 in adult hearts and thus expanded our understanding of the cellular function and pathophysiological roles of miRNAs.
LinkOut: [PMID: 17344217]
|
MiRNA-Target Expression Profile | |||||||
---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
122 hsa-miR-133a-3p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT000325 | RHOA | ras homolog family member A | 1 | 2 | ||||||||
MIRT000327 | CDC42 | cell division cycle 42 | 4 | 2 | ||||||||
MIRT000328 | ERG | ERG, ETS transcription factor | 1 | 1 | ||||||||
MIRT000329 | HCN4 | hyperpolarization activated cyclic nucleotide gated potassium channel 4 | 2 | 1 | ||||||||
MIRT000330 | UCP2 | uncoupling protein 2 | 2 | 2 | ||||||||
MIRT000331 | KRT7 | keratin 7 | 2 | 2 | ||||||||
MIRT001203 | CACNA1C | calcium voltage-gated channel subunit alpha1 C | 3 | 1 | ||||||||
MIRT001204 | HCN2 | hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2 | 4 | 2 | ||||||||
MIRT001816 | PKM | pyruvate kinase, muscle | 1 | 1 | ||||||||
MIRT001986 | CASP9 | caspase 9 | 3 | 3 | ||||||||
MIRT002925 | KCNQ1 | potassium voltage-gated channel subfamily Q member 1 | 4 | 1 | ||||||||
MIRT003542 | FSCN1 | fascin actin-bundling protein 1 | 5 | 4 | ||||||||
MIRT004831 | KCNH2 | potassium voltage-gated channel subfamily H member 2 | 4 | 1 | ||||||||
MIRT005604 | TAGLN2 | transgelin 2 | 5 | 4 | ||||||||
MIRT005813 | LASP1 | LIM and SH3 protein 1 | 3 | 2 | ||||||||
MIRT006571 | PNP | purine nucleoside phosphorylase | 4 | 2 | ||||||||
MIRT006680 | MSN | moesin | 2 | 1 | ||||||||
MIRT007032 | EGFR | epidermal growth factor receptor | 3 | 5 | ||||||||
MIRT007088 | VKORC1 | vitamin K epoxide reductase complex subunit 1 | 1 | 1 | ||||||||
MIRT007383 | PRDM16 | PR/SET domain 16 | 1 | 2 | ||||||||
MIRT021693 | TPM1 | tropomyosin 1 | 1 | 1 | ||||||||
MIRT021695 | FBN1 | fibrillin 1 | 1 | 1 | ||||||||
MIRT021696 | FAM120C | family with sequence similarity 120C | 1 | 1 | ||||||||
MIRT021697 | BCAN | brevican | 1 | 1 | ||||||||
MIRT021698 | TCTEX1D2 | Tctex1 domain containing 2 | 1 | 1 | ||||||||
MIRT021699 | ARL6IP1 | ADP ribosylation factor like GTPase 6 interacting protein 1 | 1 | 1 | ||||||||
MIRT021700 | RFT1 | RFT1 homolog | 1 | 1 | ||||||||
MIRT021701 | SENP1 | SUMO1/sentrin specific peptidase 1 | 1 | 1 | ||||||||
MIRT021702 | SMIM14 | small integral membrane protein 14 | 1 | 1 | ||||||||
MIRT021703 | PRELID1 | PRELI domain containing 1 | 1 | 1 | ||||||||
MIRT021704 | CNN2 | calponin 2 | 3 | 3 | ||||||||
MIRT021705 | ARPC5 | actin related protein 2/3 complex subunit 5 | 4 | 2 | ||||||||
MIRT021706 | FTL | ferritin light chain | 2 | 2 | ||||||||
MIRT021707 | CERS2 | ceramide synthase 2 | 1 | 1 | ||||||||
MIRT021708 | SEC61B | Sec61 translocon beta subunit | 1 | 1 | ||||||||
MIRT021709 | PLEKHA3 | pleckstrin homology domain containing A3 | 1 | 1 | ||||||||
MIRT021710 | EGFL7 | EGF like domain multiple 7 | 1 | 1 | ||||||||
MIRT021711 | VEGFA | vascular endothelial growth factor A | 1 | 1 | ||||||||
MIRT021712 | PIK3R2 | phosphoinositide-3-kinase regulatory subunit 2 | 1 | 1 | ||||||||
MIRT021713 | RGS3 | regulator of G protein signaling 3 | 1 | 1 | ||||||||
MIRT021714 | COL1A1 | collagen type I alpha 1 chain | 4 | 1 | ||||||||
MIRT021715 | GSTP1 | glutathione S-transferase pi 1 | 2 | 1 | ||||||||
MIRT035537 | SP1 | Sp1 transcription factor | 2 | 2 | ||||||||
MIRT035579 | KLF15 | Kruppel like factor 15 | 1 | 1 | ||||||||
MIRT045837 | NR4A2 | nuclear receptor subfamily 4 group A member 2 | 1 | 1 | ||||||||
MIRT052647 | BCL2L1 | BCL2 like 1 | 4 | 2 | ||||||||
MIRT052648 | MCL1 | MCL1, BCL2 family apoptosis regulator | 4 | 2 | ||||||||
MIRT053333 | RFFL | ring finger and FYVE like domain containing E3 ubiquitin protein ligase | 4 | 1 | ||||||||
MIRT054310 | IGF1R | insulin like growth factor 1 receptor | 3 | 2 | ||||||||
MIRT055599 | FAM160B1 | family with sequence similarity 160 member B1 | 2 | 2 | ||||||||
MIRT081957 | UBA2 | ubiquitin like modifier activating enzyme 2 | 4 | 1 | ||||||||
MIRT437400 | MMP14 | matrix metallopeptidase 14 | 3 | 1 | ||||||||
MIRT437953 | ANXA2 | annexin A2 | 4 | 1 | ||||||||
MIRT437954 | SNX30 | sorting nexin family member 30 | 4 | 1 | ||||||||
MIRT437955 | SGMS2 | sphingomyelin synthase 2 | 4 | 1 | ||||||||
MIRT438719 | PDLIM5 | PDZ and LIM domain 5 | 3 | 1 | ||||||||
MIRT452802 | PACS2 | phosphofurin acidic cluster sorting protein 2 | 2 | 2 | ||||||||
MIRT462823 | BCL3 | B-cell CLL/lymphoma 3 | 2 | 2 | ||||||||
MIRT468494 | SESN2 | sestrin 2 | 2 | 2 | ||||||||
MIRT477714 | EFHD2 | EF-hand domain family member D2 | 2 | 2 | ||||||||
MIRT483852 | EMID1 | EMI domain containing 1 | 2 | 2 | ||||||||
MIRT490039 | PRRT2 | proline rich transmembrane protein 2 | 2 | 2 | ||||||||
MIRT491349 | CDKN1A | cyclin dependent kinase inhibitor 1A | 2 | 4 | ||||||||
MIRT504443 | MC2R | melanocortin 2 receptor | 2 | 2 | ||||||||
MIRT505701 | SESN3 | sestrin 3 | 2 | 2 | ||||||||
MIRT513521 | RHOQ | ras homolog family member Q | 2 | 4 | ||||||||
MIRT517423 | HIST2H2AC | histone cluster 2 H2A family member c | 2 | 2 | ||||||||
MIRT526599 | DCAKD | dephospho-CoA kinase domain containing | 2 | 2 | ||||||||
MIRT528904 | THBS2 | thrombospondin 2 | 2 | 2 | ||||||||
MIRT533060 | ZBTB37 | zinc finger and BTB domain containing 37 | 2 | 2 | ||||||||
MIRT534126 | SNX33 | sorting nexin 33 | 2 | 2 | ||||||||
MIRT534700 | RNF103-CHMP3 | RNF103-CHMP3 readthrough | 2 | 4 | ||||||||
MIRT535732 | MYPN | myopalladin | 2 | 2 | ||||||||
MIRT538529 | CHMP3 | charged multivesicular body protein 3 | 2 | 4 | ||||||||
MIRT550878 | IBA57 | IBA57 homolog, iron-sulfur cluster assembly | 2 | 2 | ||||||||
MIRT551260 | PSMG1 | proteasome assembly chaperone 1 | 2 | 2 | ||||||||
MIRT551981 | UGT2B10 | UDP glucuronosyltransferase family 2 member B10 | 2 | 2 | ||||||||
MIRT553866 | SYAP1 | synapse associated protein 1 | 2 | 2 | ||||||||
MIRT558810 | CDK5R1 | cyclin dependent kinase 5 regulatory subunit 1 | 2 | 2 | ||||||||
MIRT559367 | ATP13A3 | ATPase 13A3 | 2 | 2 | ||||||||
MIRT560941 | ZFP28 | ZFP28 zinc finger protein | 2 | 2 | ||||||||
MIRT565461 | SUPT16H | SPT16 homolog, facilitates chromatin remodeling subunit | 2 | 2 | ||||||||
MIRT566234 | PTMA | prothymosin, alpha | 2 | 2 | ||||||||
MIRT568217 | C11orf24 | chromosome 11 open reading frame 24 | 2 | 2 | ||||||||
MIRT608912 | NCDN | neurochondrin | 2 | 6 | ||||||||
MIRT613229 | CCDC39 | coiled-coil domain containing 39 | 2 | 2 | ||||||||
MIRT623563 | ITPKB | inositol-trisphosphate 3-kinase B | 2 | 2 | ||||||||
MIRT637224 | TMEM59 | transmembrane protein 59 | 2 | 2 | ||||||||
MIRT641669 | CCNI | cyclin I | 2 | 2 | ||||||||
MIRT644440 | ALDOC | aldolase, fructose-bisphosphate C | 2 | 2 | ||||||||
MIRT644755 | TXNRD3NB | thioredoxin reductase 3 neighbor | 2 | 2 | ||||||||
MIRT646711 | PDE1A | phosphodiesterase 1A | 2 | 2 | ||||||||
MIRT647577 | RBMXL1 | RNA binding motif protein, X-linked like 1 | 2 | 2 | ||||||||
MIRT647760 | RNF168 | ring finger protein 168 | 2 | 2 | ||||||||
MIRT649267 | C17orf64 | chromosome 17 open reading frame 64 | 2 | 2 | ||||||||
MIRT651238 | ZMAT4 | zinc finger matrin-type 4 | 2 | 2 | ||||||||
MIRT652146 | TRIM71 | tripartite motif containing 71 | 2 | 2 | ||||||||
MIRT657168 | IP6K1 | inositol hexakisphosphate kinase 1 | 2 | 2 | ||||||||
MIRT668302 | FOSL2 | FOS like 2, AP-1 transcription factor subunit | 2 | 2 | ||||||||
MIRT687546 | MLEC | malectin | 2 | 2 | ||||||||
MIRT690857 | PLEKHG2 | pleckstrin homology and RhoGEF domain containing G2 | 2 | 2 | ||||||||
MIRT697060 | PSMC4 | proteasome 26S subunit, ATPase 4 | 2 | 2 | ||||||||
MIRT699725 | SERPINH1 | serpin family H member 1 | 2 | 2 | ||||||||
MIRT700858 | PER2 | period circadian clock 2 | 2 | 2 | ||||||||
MIRT705068 | C4orf29 | abhydrolase domain containing 18 | 2 | 2 | ||||||||
MIRT709496 | ANGPT4 | angiopoietin 4 | 2 | 2 | ||||||||
MIRT713925 | PIGR | polymeric immunoglobulin receptor | 2 | 2 | ||||||||
MIRT716058 | SFTPB | surfactant protein B | 2 | 2 | ||||||||
MIRT716724 | APOL6 | apolipoprotein L6 | 2 | 2 | ||||||||
MIRT721677 | CMTM4 | CKLF like MARVEL transmembrane domain containing 4 | 2 | 2 | ||||||||
MIRT723379 | NFAM1 | NFAT activating protein with ITAM motif 1 | 2 | 2 | ||||||||
MIRT731340 | IGF1 | insulin like growth factor 1 | 1 | 1 | ||||||||
MIRT731591 | ZEB1 | zinc finger E-box binding homeobox 1 | 1 | 1 | ||||||||
MIRT732526 | PTBP1 | polypyrimidine tract binding protein 1 | 2 | 0 | ||||||||
MIRT732527 | KDM5C | lysine demethylase 5C | 2 | 0 | ||||||||
MIRT732589 | BCL2 | BCL2, apoptosis regulator | 2 | 0 | ||||||||
MIRT732590 | CASP3 | caspase 3 | 2 | 0 | ||||||||
MIRT733594 | PPP2CA | protein phosphatase 2 catalytic subunit alpha | 3 | 0 | ||||||||
MIRT735355 | MB | myoglobin | 1 | 0 | ||||||||
MIRT735744 | CDCA8 | cell division cycle associated 8 | 3 | 0 | ||||||||
MIRT736984 | SET | SET nuclear proto-oncogene | 1 | 0 | ||||||||
MIRT737550 | TGFB1 | transforming growth factor beta 1 | 4 | 0 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|